PreTect SEE

PreTect SEE is ideal as a quality control test for NILM cytology. It is an assay for the qualitative detection of the presence of Human Papillomavirus, HPV, E6/E7 oncogene mRNA from carcinogenic HPV types 16, 18 and 45.

PreTect SEE shows high clinical specificity, supported by a low positive rate in the general population.

This CE-IVD kit identify women that have carcinogenic expression of high-risk HPV types that may induce cervical cancer. Co-testing with PreTect SEE and Cytology will therefore improve the existing screening program sensitivity without an excessive follow-up workload.

With its high capacity and low cost the test is also ideal as stand-alone test in low-income countries.




Clinical Benefits

  • Qualitative detection of E6/E7 mRNA expression from HPV 16, 18, 45
  • Intrinsic sample control ensuring sample adequacy
  • High clinical specificity minimising unnecessary interventions
  • High PPV for CIN2+
  • Low positivity rate in general population
  • CE-IVD kit
  • Enhanches identification of cervical adenocarcinoma


Test Information


Contact us

For more information about PreTect's products or ordering, please fill out the form below or send an email to



Individual HPV genotyping E6/E7 mRNA HPV 16, 18 and 45
Intrinsic Sample Control (ISC): Targeting mRNA from housekeeping gene
Sample type: Cervical samples
Preservatives: PreTect TM (PreTect AS)
  PreservCyt/ThinPrep (Hologic)
  SurePath (BD Diagnostics)
Input-material: Isolated Nucleic Acid (DNA/RNA)*
Technology: Real time NASBA
  Isothermal amplification (41°C)
  Four specific molecular beacons
Format: 96-well PCR plate
  Pre-filled with reagents
Assay time: ~ 150 minutes
Instrumentation: Fluorescence reader /
  RT-PCR (CFX-96/QuantStudio5)